PolyPid (NASDAQ:PYPD) Rating Reiterated by HC Wainwright

PolyPid (NASDAQ:PYPD)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $14.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 240.63% from the stock’s current price.

PolyPid Price Performance

PYPD stock opened at $4.11 on Tuesday. The business has a 50 day moving average price of $4.50 and a 200 day moving average price of $5.14. The stock has a market cap of $19.73 million, a price-to-earnings ratio of -0.33 and a beta of 1.31. PolyPid has a fifty-two week low of $3.57 and a fifty-two week high of $12.60. The company has a quick ratio of 1.64, a current ratio of 1.64 and a debt-to-equity ratio of 0.60.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, May 8th. The company reported ($1.37) earnings per share for the quarter, topping the consensus estimate of ($1.96) by $0.59. Equities research analysts anticipate that PolyPid will post -3.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PolyPid

An institutional investor recently bought a new position in PolyPid stock. Rosalind Advisors Inc. bought a new stake in PolyPid Ltd. (NASDAQ:PYPD) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid accounts for approximately 1.8% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 20th largest holding. Rosalind Advisors Inc. owned approximately 8.67% of PolyPid at the end of the most recent reporting period. 26.47% of the stock is owned by institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.